156 results about "Gastrointestinal tract" patented technology

This invention relates to a method for detecting colorectal cancer tumor cell-associated microorganisms, specifically a method for eliminating intestinal fecal microbial contamination and detecting colorectal cancer tumor-associated microorganisms, belonging to the field of biotechnology. This invention initially eliminates fecal microbial contamination from the sample structure by coarsely shearing and enzymatically digesting the intestinal folds and villi; then, it uses a 40μm cell sieve to filter out incompletely digested tissue fragments, further eliminating intestinal fecal bacteria contamination, and collecting a single-cell suspension; subsequently, the collected single-cell suspension is repeatedly washed with 300g centrifugation to remove as many intercellular or loosely bound "transient bacteria" as possible, retaining intracellular and firmly colonized microorganisms. Ultimately, this eliminates the severe contamination from the large and complex fecal microorganisms, allowing the detection of tumor cell-associated microorganisms, which are already present in low biomass. This method is suitable for detecting microorganisms in gastrointestinal tissues that are in direct contact with the environment.

The present invention relates to nutritional compositions comprising digestible carbohydrates, lipids, proteins, 3-fucosyl lactose (3-FL) and a butyrate source, which are suitable for providing nutrition to an infant or young child suffering from or at risk of developing a food allergy, preferably cow milk protein or egg allergy, wherein the protein is or consists essentially of hydrolysed protein and / or free amino acids, and wherein the butyrate is provided in the form of dietary butyrate and / or by non-digestible saccharides selected from non-digestible polysaccharides, non-digestible oligosaccharides or mixtures thereof capable of undergoing microbial fermentation in the gastrointestinal tract to produce butyrate, and uses thereof.

The present invention relates to immunoglobulin single variable domains (ISVDs) for the treatment of diseases by the enteral, e.g. oral, delivery. In particular, the present invention provides ISVDs comprising sequences with a high percentage of sequence identity to SEQ ID NO: 1 for such enteral administration. Such sequences were identified as extraordinarily stable in the gastrointestinal tract, which prevents their degradation and thereby allows them to exert a strong therapeutic effect.

The application discloses a tripterine self-assembled nanoparticle microsphere, a preparation method and application thereof, and belongs to the technical field of biological medicines. The tripterine self-assembled nanoparticle microsphere takes tripterine self-assembled nanoparticles as a drug core, is formed by cross-linking of a sodium alginate-pectin composite carrier through calcium ions, can significantly improve drug solubility, realizes stable protection and intestinal targeting rapid release in the gastrointestinal tract, and effectively reduces drug systemic exposure and side effect risks. The preparation process is mild and simple, the obtained preparation has high targeting and safety. Pharmacodynamic results show that the microsphere can obviously improve liver steatosis, inflammation and fibrosis related to metabolic-related fatty liver hepatitis, and has better curative effect than conventional preparations. The application provides a novel oral delivery system for preventing and treating metabolic-related fatty liver hepatitis, and has good industrial and clinical transformation prospects.

The application provides bacillus velezensis LW56-4 and application thereof. The bacillus velezensis is bacillus velezensis LW56-4, the classification name is Bacillus velezensis , and the preservation address is China.Wuhan.Wuhan University, and the preservation number is CCTCC NO: M 20251875. The bacillus velezensis LW56-4 has broad-spectrum antibacterial property, can reduce animal diarrhea, promote animal gastrointestinal development and improve antioxidant capacity, can effectively promote feed conversion and promote animal growth, and is an ideal substitute for aureomycin and other antibiotics.

The invention discloses a fattening feed additive composition for old cattle and a fattening method, and belongs to the technical field of feed. The additive composition comprises the following components in parts by weight: 13-20 parts of a rumen function regulator, 4-10 parts of an intestinal repair agent, 10-20 parts of a rumen bypass compound enzyme preparation, 5-10 parts of a muscle-increasing growth-promoting composition, 5.5-7.3 parts of a functional trace element composition and 32.7-62.5 parts of a carrier. Wherein the rumen function regulator is compounded by a coated saccharomyces cerevisiae culture and bacillus subtilis; the rumen bypass compound enzyme preparation comprises acid protease, neutral protease and cellulase; the muscle-building and growth-promoting combination is coated guanidinoacetic acid. Through regulation and control of a rumen-intestinal tract-tissue three-level linkage network, the rumen fermentation function of the old cattle is remarkably improved, the feed conversion rate is increased, and meanwhile muscle hyperplasia and meat tenderization are achieved. By means of the fattening method, the average daily gain of the old cattle is increased by 22.8% or above, the muscle shear force is reduced by 29.6% or above, the feed conversion ratio is reduced by 17.1% or above, and green and efficient fattening is achieved.

This invention discloses a method and apparatus for modeling the gastric emptying characteristics of compressed dry food. The method includes: obtaining a set of gastrointestinal digestive enzyme concentration ranges; the set of gastrointestinal digestive enzyme concentration ranges includes salivary amylase concentration range, pepsin concentration range, and pancreatic enzyme concentration range; based on the set of gastrointestinal digestive enzyme concentration ranges, performing measurement processing on the compressed dry food to obtain a set of gastric retention rate values; and performing gastric emptying characteristic modeling on the set of gastric retention rate values ​​to obtain a set of gastric emptying models.

The present invention relates to a liposome composition for oral administration, the composition comprising a GLP-1 analog. The liposome according to the present invention has both excellent encapsulation efficiency and encapsulation content of the GLP-1 analog drug, and the prepared liposome composition resists digestive enzymes in the gastrointestinal tract and does not easily degrade when administered orally, thus having excellent stability, and has a high absorption rate in the body, and thus exhibits excellent pharmacological effects.

The present invention relates to a pharmaceutical composition comprising avatrombopag maleate or one of its pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient manufactured by using dry granulation with improved pharmaceutical characteristics to obtain proper release profiles in three different physiological media of gastrointestinal tract.

The invention patent is titled "Dragon and Cypress Gel," belonging to the pharmaceutical category. The main components of Dragon and Cypress Gel are: Phellodendron bark, earthworm, dragon's blood, Oldenlandia diffusa, Sophora flavescens, and Bletilla striata. In recent years, research on cervicitis and cervical lesions has shown good results using external treatments of traditional Chinese medicine. Vaginal cervical medications are characterized by high local drug concentration, low dosage, and safety and effectiveness, receiving high clinical evaluation. The vagina and cervix have abundant capillaries and lymphatic vessels, and lack clearly defined nerve endings, resulting in minimal pain stimulation for patients during administration. This makes it an effective drug release site for specific diseases such as cervicitis and vaginitis. Traditional Chinese medicine gels are a novel type of external preparation of traditional Chinese medicine. They are made by dissolving or uniformly dispersing traditional Chinese medicine in a gel. These gels adhere tightly to the treatment site for a relatively long time, exhibiting good bioadhesion, and are simple to prepare. It is suitable for use on skin, mucous membranes and cavities. It not only avoids the first-pass effect of enzymes and acids in the gastrointestinal tract that exists in oral administration, but also reduces the adverse reactions of drugs. It has the characteristics of good spreadability, non-greasy feeling, easy to wash off, good transdermal absorption, and comfortable use.

The present invention discloses a guarana extract – EGCG synergistic fat-burning composition, belonging to the technical field of functional foods and weight management. The composition comprises guarana extract, epigallocatechin gallate, and konjac glucomannan. By controlling the component ratio and key parameters, a dynamic gel network formed by konjac glucomannan provides in-situ protection of active ingredients and enables programmed release in the gastrointestinal tract, while constructing a multi-level appetite-suppression system with temporal continuity.The invention overcomes problems in the prior art, including poor stability, low bioavailability, and fragmented appetite regulation, and achieves synergistic effects in fat burning and intake control. It is suitable for preparing oral solid formulations, with high safety, good stability, and suitability for large-scale industrial production and commercialization.

This invention relates to an oral nanomedicine antigen delivery system and its construction method and application, belonging to the field of oral nanomaterials technology; the construction method includes the following steps: (1) preparation of OM nanoparticle suspension; (2) preparation of cationic liposome suspension; (3) preparation of cationic liposome suspension loaded with OM / BF; (4) construction of oral nanomedicine antigen delivery system. This invention breaks through multiple barriers in the gastrointestinal tract, improves drug bioavailability, and achieves precise immune tracking through the OVA tumor antigen model, simulating in vivo anti-tumor CTL response, thereby exerting anti-tumor effects synergistically at the cellular, tissue, and immune levels, effectively solving the problems of poor water solubility and low delivery efficiency of the active ingredient bufotoxin in traditional Chinese medicine. At the same time, through macrophage-mediated immune regulation and precise drug release, it improves targeting and treatment efficiency, opening up a new avenue for tumor immunotherapy with oral nanomedicine.

The present application relates to a kind of compound moxidectin pour-on and its preparation method and application, specifically to a kind of compound moxidectin pour-on, component mass mass fraction ratio includes: 0.1-5 portion moxidectin, 5-30 portion benzimidazole anthelmintic, 30-70 portion solvent, 5-20 portion solubilizer, 0.1-2 portion antioxidant, 10-30 portion transdermal enhancer.The present application not only covers gastrointestinal nematode, tapeworm, fluke and other various parasites, but also has killing or inhibiting effect on larva, worm egg, solve the problem of single component anthelmintic spectrum narrow, specific parasite effect is not good.

The application discloses an alcohol-free matcha lees with antioxidant activity and a preparation method thereof, and belongs to the technical field of food fermentation. The application provides the alcohol-free lees with antioxidant activity, the alcohol content of the alcohol-free lees is very low (<0.5% Vol), the stimulation to gastric mucosa is reduced, the alcohol-free lees is friendly to the gastrointestinal tract, is high in safety, and is suitable for a wide range of people; the lees is matched with matcha, the glycemic index is optimized, the fermentation benefits of traditional lees are retained and enhanced, the additional matcha can bring antioxidant substances such as tea polyphenols, the aroma of ordinary lees is enhanced, and the alcohol-free matcha lees has green tea fragrance; compared with glutinous rice lees, the SOD activity of the alcohol-free matcha lees is enhanced by 13.81 times, the ABTS activity is enhanced by 11.07 times, the iron ion reduction capacity is enhanced by 3.87 times, and the DPPH clearance rate is enhanced by 1.61-4.70 times. The alcohol-free matcha lees can be drunk all day round, is flexible in matching, and can be developed into alcohol-free beverages, milk tea, dessert bases and the like.

Provided herein is a particle made of a protein covalently bound to a prebiotic carbohydrate, thereby forming a conjugate, wherein at least two said conjugates are covalently crosslinked via their carbohydrate units (e.g. by a phospho-di-ester bond). The said particle may be used for selectively promoting probiotic bacteria growth in the colon and may be used to deliver additional probiotic growth factors, or other bioactives and drugs to the colon. Furthermore, provided herein are methods for preparing the particle, and for delivering a substance bound to, or entrapped within the particle, into the gastrointestinal tract of a subject in need thereof.

This invention provides a *Lactobacillus reuteri* AUI2506 strain and its applications. The *Lactobacillus reuteri* AUI2506 strain of this invention is a probiotic that grows rapidly, requires simple fermentation conditions, is biosafe, and exhibits good acid and bile salt tolerance, auto-aggregation ability, and surface hydrophobicity. It survives for a long time and maintains high activity in the gastrointestinal tract, contributing to positive health effects. Furthermore, this strain possesses antioxidant, anti-inflammatory, weight-loss, blood sugar-lowering, and adjunctive blood sugar-lowering effects, filling a gap in existing technologies and providing a new and effective means to improve metabolic health.

Orally administered pharmaceutical compositions comprising incretin or its analogues or derivatives are presented, which allow for prolonged glycemic control. The formulations presented herein incorporate a self-emulsifying drug delivery system (SEDDS). Advantageously, such formulations provide protection in the upper gastrointestinal tract from proteolytic conditions while allowing for efficient drug release and absorption in the lower gastrointestinal tract.

The application belongs to the technical field of biological medicine, and specifically discloses a nano delivery system and a preparation method and application thereof. mEVs are used as a core to encapsulate a depressor peptide QIGLF, a positively charged K5 is used to form an intermediate layer, the structural stability of the system is enhanced, and cell uptake is promoted, finally, a negatively charged Pec is used to form an outer protective shell, the stability and anti-enzymatic ability of the nanoparticles in the gastrointestinal environment are improved, and a core-shell multi-layer structure is constructed. The Pec can remain stable in the gastrointestinal tract, resist the destruction of gastric acid and digestive enzymes, and realize the responsive release of the core and the depressor peptide through specific degradation of the intestinal flora in the colon environment, and the K5 further enhances the uptake of the nanoparticles by the colon epithelial cells, thereby ensuring the efficient absorption of the depressor peptide. The nano delivery system has the comprehensive advantages of structural stability, intestinal retention, colon targeting and biological functionality during oral delivery, and provides an innovative solution for the efficient and safe application of the oral depressor peptide.

The application belongs to the technical field of biological medicine, and discloses a novel polypeptide with lipid-lowering effect. In view of the problem that polypeptides are prone to be enzymolyzed in the gastrointestinal tract and difficult to play obvious effect in the body, a novel polypeptide is designed, and the amino acid sequence of the polypeptide is GQAIWMY. The polypeptide GQAIWMY has lipid-lowering capacity, is not prone to be degraded by gastrointestinal enzymes and is more stable, and can be used for preparing drugs for preventing or treating cardiovascular diseases (such as hyperlipidemia, atherosclerosis, coronary heart disease) and fatty liver diseases.

Compositions in the form of oil-based solutions that form oil-in-water (OIW) microemulsions in the aqueous environment of the GI tract when taken orally via a hard or soft capsule are described. The resulting microemulsions that form from the oil-based solution within the GI tract can rapidly deliver oil-soluble species and alcohol-soluble species (including PEG derivative assisted alcohol-soluble species) deliverables to the bloodstream through the tissues forming the GI tract. The in situ formed microemulsions resulting from consumption of the encapsulated oil-based solutions include oil-phase microemulsion droplets of monolayer surfactant bound particles suspended in the aqueous continuous phase of the GI tract. The oil-based solutions also may in situ form water-core liposomes suspended in the aqueous continuous phase of the GI tract.

This invention discloses a strain of Zygosaccharomyces rouxii, DL-WSY01, and its applications, belonging to the field of food biotechnology. This invention provides a strain of Zygosaccharomyces rouxii, DL-WSY01, with accession number CGMCC No. 25335. The DL-WSY01 strain exhibits rapid growth and excellent fermentation performance; it is also tolerant to the gastrointestinal environment, demonstrating good probiotic properties; it is sensitive to common fungal antibiotics, non-hemolytic, and exhibits good safety; it effectively tolerates high salt, acid, and ethanol; it possesses antioxidant properties; it can produce high levels of ethanol; it can also produce high levels of flavor compounds and has biogenic amine degradation capabilities. Therefore, this strain, as a starter culture, can ensure the safety and flavor quality of fermented foods such as fermented soybean paste and soybean paste, and significantly improve the nutritional value of fermented foods.

Provided are a recombinant microorganism expressing a vasoactive intestinal peptide (VIP) gene, and a composition including the microorganism for preventing or treating a disease causing damage to the gastrointestinal tract.

The application provides a traditional Chinese medicine composition for preventing and treating metabolic-related fatty liver disease combined with type 2 diabetes and application thereof, and the traditional Chinese medicine composition is made of raw materials in the following weight parts: 6-30 parts of Huangqi, 0-20 parts of Ganjiang, 4-20 parts of Shaoyao, 4-20 parts of Gancao and 2-30 parts of Dazao. The medicine provided by the application can simultaneously significantly improve the abnormal glucose metabolism and liver metabolism damage of a "sugar-liver comorbidity" model animal, realizes integrated intervention on a core pathological link of the disease, can produce an unexpected integrated treatment effect on the "sugar-liver comorbidity", significantly reduces adverse reactions of diarrhea, improves gastrointestinal tolerance, is more suitable for the core pathogenesis of the "sugar-liver comorbidity" with cold and heat mixed together, and is beneficial to improving long-term medication safety.

This invention discloses a slow-digesting quinoa flour-concentrated milk protein composite gel food and its preparation method, belonging to the field of food processing technology. The invention first protects the composition as a gel food prepared from raw materials containing concentrated milk protein and quinoa flour; the preparation includes premixing quinoa flour and a portion of concentrated milk protein, hydrating them to obtain a premix with a starch-protein network, adding the remaining raw materials, stirring to form a slurry, and then shaping it. The gel food of this invention constructs a dense and continuous starch-protein network. This network, on the one hand, acts as a physical barrier to prevent effective contact between gastrointestinal digestive enzymes and internal proteins, maintaining the stability of the protein's secondary structure, thereby slowing down the rate of protein digestion and hydrolysis in the gastrointestinal tract to achieve slow digestion; on the other hand, it directly improves the product's hardness, chewiness, and other textural parameters, enhances water-holding capacity, reduces water separation rate, optimizes color and flavor, and achieves a synergistic improvement in multiple indicators of edible quality.

To provide a pediatric surgical device for removing metal objects from the digestive tract. [Solution] The pediatric surgical device has an adjustable frame 1, with position-limiting rings 2 fixedly connected to both the left and right side walls of the adjustable frame, a contact plate 3 provided above the adjustable frame, a sliding rod 4 fixedly connected to the lower end of the contact plate, the lower end of the sliding rod passing through the upper side wall of the adjustable frame and fixedly connected to a traction rope 7, an elastic storage mechanism 6 provided at the lower end of the extension outer tube 5, and a clamping mechanism provided at the lower end of the traction rope. By installing the elastic storage mechanism, the entire foreign object is softly encased after being clamped, preventing the corners of the foreign object or the edges of the instrument from injuring the gastrointestinal mucosa, thereby significantly improving the safety of pediatric surgical procedures.

The application discloses ecdysterone-low molecular weight fructan composite microspheres with fat-reducing and muscle-increasing functions, and a preparation method and application thereof, and belongs to the technical field of biological medicine and functional food. The composite microspheres have a core-shell structure, the inner core is a calcium alginate gel, the outer shell is chitosan, the inner core co-encapsulates ecdysterone and low molecular weight fructan, and the mass ratio of the two is 0.8-1.2:1. The preparation adopts a liquid drop microfluidic technology combined with an internal gelation method to form the inner core, and adopts a post-crosslinking method to coat the outer shell. The composite microspheres are regular in shape, uniform in particle size, high in encapsulation rate, good in stability, excellent in pH response slow-release and anti-degradation characteristics in the gastrointestinal tract. In-vivo pharmacological experiments prove that the composite microspheres can reduce the body weight and body fat rate of obese mice, increase the lean meat content and muscle strength, realize synergistic effects of fat reduction and muscle increase, and can be used for preparing drugs or functional food for improving obesity-related muscle loss, low-muscle obesity and related metabolic syndrome.

Compositions and principles for use before parturition in the prophylactic treatment of hypocalcemia in ruminant animals include compositions having phosphate binders for the prophylactic treatment of parturient hypocalcemia in ruminant animals. These compositions are presented in unit dosage forms, with one or more doses administered daily to the gastrointestinal tract of the ruminant animal, or in wet form. The composition contains one or more phosphate binders and one or more nutrients selected from minerals, vitamins, and amino acids, as well as a composition that includes an inhibitor of the small intestinal Na-phosphate transporter for the prophylactic treatment of parturient hypocalcemia in ruminant animals. Phosphate binders are selected from aluminum, iron, sevelamer, and lanthanum salts, with either inorganic or organic acids, hydrates thereof, or any mixture thereof.